微信扫码关注“小狗文献”

即刻体验更多权益

文献多,下载快,翻译准

首页 > 医学词汇大全 > Daptomycin
Daptomycin

重症

关键词重症 药物 抗菌

词汇介绍

拓展阅读

解析

daptomycin

释义   达托霉素

例句   A new drug was found, daptomycin, to treat infective endocarditis.

于是出现了治疗感染性心内膜炎的新药—达托霉素。


概述

达托霉素为一环脂肽类抗生素,由1个十碳烷侧链与1个环状β氨基酸肽链N-末端的色氨酸连接而成,具有1个亲水核及1个亲脂尾。分子式为C72H101N17O26,相对分子质量为1620。达托霉素由玫瑰孢链霉菌发酵产生。2003年9月,由Cubist公司研制的新抗菌药达托霉素(商品名:Cubicin)获得美国FDA批准,用于治疗 G+菌引起的复杂性皮肤及皮肤软组织感染(cSSSI),并先在德国、英国和荷兰上市。2006年FDA又批准了达托霉素的新适应症,用于治疗由金葡球菌引起的心脏感染和菌血症。达托

Is Daptomycin plus Ceftaroline the Way To Go for Methicillin-Resistant Staphylococcus aureus Bacteremia?复制标题

耐甲氧西林金黄色葡萄球菌菌血症的去路是达托霉素加头孢罗林吗?

发表时间:2019-10-22

影响因子:4.7

作者: Kaye KS

期刊:Antimicrob. Agents Chemother.

Although bloodstream infections (BSI) due to methicillin-resistant  Staphylococcus aureus (MRSA) remain a common health care problem worldwide, clinical failure rates using guideline-concordant treatment, including vancomycin or daptomycin monotherapy, remain unacceptably high, approaching 20 to 30% in many studies,Furthermore, rates of complications including metastatic disease such as endocarditis and vertebral osteomyelitis, are extraordinarily high. Thus, innovative approaches to treatment are needed. Geriak et al. sought to determine the impact of early initiation of combination therapy (with daptomycin and ceftaroline) on clinical outcomes in patients with MRSA BSI. This was an important, albeit small, nonblinded clinical trial that demonstrated decreased mortality among patients who received daptomycin and ceftaroline compared to the standard of care (i.e., monotherapy with either vancomycin or daptomycin) . There are several limitations to the study some of which the authors recognize, including the small sample size, disproportionate randomization, the open-label nature of the trial, and the lack of a data safety monitoring board (DSMB). Despite this, the study findings are extremely important and demonstrate the need for an adequately powered, well-controlled clinical trial comparing the two treatment arms.

译文

尽管耐甲氧西林金黄色葡萄球菌(MRSA)引起的血流感染(BSI)仍然是世界范围内常见的医疗保健问题,但使用指南一致治疗(包括万古霉素或达托霉素单药治疗)的临床失败率仍然很高,在许多情况下接近20%至30%研究表明,包括转移性疾病(如心内膜炎和椎骨骨髓炎)在内的并发症发生率非常高。因此,需要创新的治疗方法。 Geriak等。力图确定早期开始联合治疗(达托霉素和头孢洛林)对MRSA BSI患者临床结局的影响。这是一项重要的,尽管很小的,无盲的临床试验,该试验表明与达标治疗(即,万古霉素或达托霉素的单一疗法)相比,接受达托霉素和头孢洛林治疗的患者死亡率降低。作者有一些认识到这项研究的局限性,包括样本量小,随机分配不成比例,试验的开放标签性质以及缺乏数据安全监控委员会(DSMB)。尽管如此,这项研究结果还是非常重要的,并且证明了需要有足够动力,控制良好的临床试验来比较两个治疗方案。